ALEC (Alector) Quality Rank


ALEC Alector Inc ALEC
30 GF Score
Price $2.01
GF Value $0.73
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Alector Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Alector Quality Rank Related Terms

ALEC
30GF Score
Alector Inc ALEC
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Alector (ALEC) Overvalued in 2026?

Based on GuruFocus' analysis, Alector stock appears to be overvalued. The current stock price of $2.01 is trading 175.3% above its estimated GF Value™ of $0.73. GuruFocus considers Alector to be Significantly Overvalued.

Key valuation signals for ALEC:

  • Quality Rank:
  • GF Value™: $0.73 vs. price of $2.01 (175.3% above fair value)
  • GF Score™: 30/100 with 7 warning signs

No single metric tells the full story. See the ALEC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alector Business Description

Address 131 Oyster Point Boulevard, Suite 600, South San Francisco, CA, USA, 94080
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.
30GF Score

Get the complete analysis for ALEC

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.01
Price
$0.73
GF Value